1. Report Introduction
2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Overview at a Glance
3. Market Share Distribution of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
4. Disease Background and Overview: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7.3. Sub-Type Specific cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
7.4. Sex- Specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
7.5. Diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7.6. Treated Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.1.3. Sub-Type Specific cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.1.4. Sex- Specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.1.5. Diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.1.6. Treated Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.2.3. Sub-Type Specific cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.2.4. Sex- Specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.2.5. Diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.2.6. Treated Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.3.3. Sub-Type Specific cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.3.4. Sex- Specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.3.5. Diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.3.6. Treated Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.4.3. Sub-Type Specific cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.4.4. Sex- Specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.4.5. Diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.4.6. Treated Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.5.3. Sub-Type Specific cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.5.4. Sex- Specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
8.5.5. Diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.5.6. Treated Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.3. Sub-Type Specific cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
9.4. Sex- Specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)*
9.5. Diagnosed Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.6. Treated Cases of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.